MedPath

A comparative study of combined perineural Dexamethasone and Dexmedetomidine versus perineural Dexamethasone alone as adjuvants to Ropivacaine in adductor canal block for postoperative analgesia in patients undergoing total knee arthroplasty.

Not yet recruiting
Conditions
Unilateral primary osteoarthritisof knee,
Registration Number
CTRI/2023/06/053586
Lead Sponsor
Tata Main Hospital
Brief Summary

This study is planned to evaluate the potential synergistic effect of dexamethasone and dexmedetomidine, which could have a substantial impact on postoperative analgesia for patients undergoing total knee arthroplasty. We hypothesize that combined perineural dexamethasone and dexmedetomidine as adjuvants to a local anesthetic mixture (Ropivacaine) will provide better postoperative analgesia than perineural dexamethasone alone with local anesthetics used in adductor canal block administered to patients undergoing total knee arthroplasty. 

Fifty-eight patients undergoing unilateral total knee arthroplasty under subarachnoid block shall be randomly divided into 2 groups (DDR & DR) of 29 patients each. Subarachnoid block shall be administered with 3 ml 0.5% heavy Bupivacaine at L3-L4 interspace in the sitting position in either group for anesthesia.  Group DDR Patients shall receive ultrasound-guided adductor canal block with 30 ml of 0.5% Ropivacaine along with  Dexamethasone 4 mg & Dexmedetomidine 50 mcg after completion of surgery. Group DR  patients shall receive ultrasound-guided adductor canal block with 30 ml of 0.5% Ropivacaine along with  Dexamethasone 4 mg and 0.5 ml of saline after completion of the surgery. The postoperative rescue analgesia will consist of Morphine PCA (Patient Controlled Analgesia). PCA setup shall be a bolus of 1 mcg with a lockout interval of 10 mins without any background infusion (maximum dose of 6 mg/h). PCA will be started on shifting the patient to the post-anesthesia care unit (PACU) and will be continued for a period of 48 h post-op. As a part of the multimodal analgesia regime, all patients will receive Paracetamol 1 gm intravenously (8 hourly) and Diclofenac 75 mg intravenous infusion (12 hourly) in the perioperative period.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
58
Inclusion Criteria

Patients undergoing elective primary unilateral total knee arthroplasty under subarachnoid block ASA grades I-III.

Exclusion Criteria

Patients refusing to participate in the study History of allergy to local anesthetics Patients with coagulopathy or infection at the site of block Patients with psychiatric illness or cognitive dysfunction who cannot use the patient-controlled analgesia (PCA) Patients having neuromuscular deficits, severe COPD, renal deficiency, severely compromised cardiovascular status Patients with body mass index (BMI) of > 35 kg/m2.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total opioid (Morphine) consumption in the first 24 hours postoperativelyTotal opioid (Morphine) consumption in the first 24 hours postoperatively
Secondary Outcome Measures
NameTimeMethod
Opioid (Morphine) consumptionAt 48 hours postoperatively
NRS pain scoresAt 3, 6, 12, 18, 24, 30, 36, 42 and 48 hours postoperatively, both at rest and with movement
Time to first requirement of rescue analgesia
Episodes of hypotension, bradycardia and desaturation
Functional outcome by TUG test (in seconds)At 48 hours postoperatively
Ramsay sedation score
Quadriceps muscle strength assessment by Manual Muscle Testing score (MMT)

Trial Locations

Locations (1)

Tata Main Hospital

🇮🇳

Singhbhum, JHARKHAND, India

Tata Main Hospital
🇮🇳Singhbhum, JHARKHAND, India
Ravi Kant
Principal investigator
8250308598
ravi_doc34@ymail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.